Michelle Vega-Olivo
Family · Philadelphia, PANPI 1619265576
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 92.6% of it on its own, with 10 other manufacturers making up the rest. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $433.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$51K
- Genentech USA, Inc.$4K
- United Therapeutics Corporation$113
- Aurinia Pharma U.S., Inc.$101
- GSK$80
- ANI Pharmaceuticals, Inc.$55
- plus $113 from 5 others
What the payments were for
- Consulting fees$10,94520%
- Speaking & faculty fees$27,80550%
- Travel & lodging$12,96324%
- Food & beverage$3,3906%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 107 | $51,043 |
| Genentech USA, Inc. | 5 | $3,598 |
| United Therapeutics Corporation | 2 | $113 |
| Aurinia Pharma U.S., Inc. | 1 | $101 |
| GSK | 4 | $80 |
| ANI Pharmaceuticals, Inc. | 3 | $55 |
| Astellas Pharma US Inc | 1 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| AstraZeneca | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,103 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 65 | $747,413 |
| OpsumitMacitentan | 34 | $435,670 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 313 | $255,680 |
| FasenraBenralizumab | 31 | $172,315 |
| NucalaMepolizumab | 27 | $143,271 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 168 | $119,662 |
| ZemairaAlpha-1-Proteinase Inhibitor | 11 | $111,120 |
| Spiriva RespimatTiotropium Bromide | 72 | $62,488 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 96 | $50,568 |
| Dupixent SyringeDupilumab | 13 | $48,707 |
| Pirfenidone | 16 | $41,665 |
| Breo ElliptaFluticasone/Vilanterol | 62 | $30,457 |
| Incruse ElliptaUmeclidinium Bromide | 78 | $29,200 |
| Spiriva HandihalerTiotropium Bromide | 30 | $23,458 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 544 | $17,587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $51,043 | $831,413175 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $80 | $516,177595 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $27 | $435,67034 claims |
| AstraZenecaFasenra, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $18 | $308,099242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Philadelphia
- Bethany ThomasPhiladelphia$126K
- Anne CalvaresiPhiladelphia$81K
- Bethany MooneyPhiladelphia$73K
- Susan Estrella-EadesPhiladelphia$61K
- Danielle LandPhiladelphia$48K
- Nicole SmithPhiladelphia$37K
- Dana SerafinPhiladelphia$31K
- Tammaris KaschakPhiladelphia$27K
- Laura NoltePhiladelphia$21K
- Christopher RenziPhiladelphia$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.